Sylvester Stallone, Maintenance, and What Happens If You Stop

By
Published Updated Last reviewed
Hormone therapy clinical care image for Sylvester Stallone, Maintenance, and What Happens If You Stop

At a glance

  • TRT use: Publicly confirmed by Stallone in multiple interviews spanning his 60s and 70s
  • HGH use: Admitted past use following a 2008 customs seizure in Australia (matter of public record)
  • Current status: Whether Stallone continues or has modified any protocol is not publicly confirmed as of this writing
  • Clinical angle: Long-term exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis; discontinuation requires careful management
  • HealthRX takeaway: Stallone's decades-long public acknowledgment of TRT is the longest-documented celebrity history in this space, making him an anchor for clinically grounded discussion

The Public Record: What Stallone Has Actually Said

Sylvester Stallone confirmed his testosterone use in a 2008 Time magazine interview, telling the outlet that testosterone was "just something I believe in" and describing it as part of his approach to aging and body maintenance. He repeated similar sentiments in subsequent years, publicly framing testosterone therapy as a tool for energy and composition as he moved through his 60s and 70s. These are his words, on the record.

The HGH piece of his history is a separate, documented event. In February 2008, Australian customs officials seized vials of Jintropin (a brand of recombinant human growth hormone) from Stallone's luggage upon arrival in Sydney. Stallone pleaded guilty in a Sydney court to illegally importing the hormone and paid a fine. He subsequently acknowledged the use publicly, describing it in at least one interview as something he had used for recovery. That incident is a matter of Australian court record and was reported by multiple major outlets including Reuters and the BBC.

What is not publicly confirmed: his precise dosing history, whether a supervising physician prescribed his testosterone under a formal hypogonadism diagnosis, the exact duration of any HGH protocol, and whether he continues any form of TRT or peptide therapy today. The HealthRX Medical Team will not state any of those details as fact.

Why This Public Story Matters

Stallone occupies an unusual position in this conversation. Most celebrities who use or are speculated to use TRT do so with minimal public comment. Stallone, by contrast, has been open over more than fifteen years, framing hormone therapy as a reasonable tool for men navigating aging. That openness, combined with his visible physique across decades of films, has made him a default reference point in media coverage of men's longevity medicine.

The clinical question his public profile raises is one that any man on long-term testosterone replacement should ask: if you have been on exogenous testosterone for years, what are the real physiological stakes of maintaining the protocol versus stopping it?

What Long-Term TRT Does to the Hypothalamic-Pituitary-Gonadal Axis

When exogenous testosterone enters the system, the hypothalamus detects elevated androgen levels and reduces its secretion of gonadotropin-releasing hormone (GnRH). The pituitary follows, cutting output of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Without LH stimulation, the Leydig cells in the testes stop producing endogenous testosterone. Without FSH, spermatogenesis is suppressed. This feedback suppression is well-characterized in the literature and is dose-dependent and duration-dependent: the longer and higher the exposure, the deeper the suppression. A 2014 review in the Journal of Clinical Endocrinology and Metabolism documented that HPG axis recovery after TRT discontinuation can take months to over a year, with some older men showing incomplete recovery.

For men who began TRT in the context of true hypogonadism (serum testosterone consistently below 300 ng/dL, with symptoms), the pre-treatment baseline was already low. Discontinuation in that population returns them to a state of deficiency, not to a normal set-point. For men who began TRT at borderline or age-related levels, the picture is more variable.

What Happens When You Stop: The Clinical Picture

Discontinuation of testosterone therapy produces a predictable clinical sequence. In the first days to weeks, free and total testosterone levels fall as the exogenous supply is withdrawn. Because the HPG axis has been suppressed, endogenous production does not immediately compensate. The result is a transient or prolonged period of hypogonadism, sometimes called "testosterone withdrawal" in the clinical shorthand, though the formal term is secondary hypogonadism induced by exogenous androgen suppression.

Symptoms during this window can include fatigue, decreased libido, mood changes, reduced muscle mass, and increased adiposity. Men who had significant body composition benefits from TRT often notice regression in lean mass and increases in fat mass within weeks to months of stopping, because skeletal muscle is acutely sensitive to androgen signaling. A 2001 study in the New England Journal of Medicine showed that testosterone dose correlated directly with fat-free mass gains and inversely with fat mass in healthy young men, underscoring how quickly composition can shift with androgen changes.

HPG axis recovery varies considerably by age. Younger men (under 40) who have been on TRT for fewer than two to three years typically recover endogenous production within three to six months, often assisted by protocols using clomiphene citrate or human chorionic gonadotropin (hCG) to stimulate LH-like signaling. Older men, particularly those in their 60s or 70s, face steeper recovery challenges because baseline LH responsiveness and Leydig cell reserve both decline with age independently of TRT. A 2020 paper in Andrology found that men over 60 who discontinued TRT had significantly longer recovery timelines and a higher rate of incomplete HPG recovery compared to younger cohorts.

The HealthRX Medical Team perspective: For a man in his 60s or 70s who has been on testosterone for a decade or more, discontinuation is not simply "stopping a medication." It is a physiological transition that requires clinical supervision, a recovery protocol if fertility or HPG recovery is a goal, and realistic expectation-setting around timeline. Doing this unilaterally, without physician guidance, risks a prolonged hypogonadal state that is objectively worse than either continuing therapy or tapering with support.

If You Continue: Long-Term Monitoring Considerations

For men who remain on TRT long-term, the clinical literature identifies several parameters that require ongoing surveillance. These are not theoretical risks specific to Stallone; they apply to any man on the protocol.

Hematocrit and erythrocytosis. Testosterone stimulates erythropoiesis. Chronic elevation of hematocrit above 54% increases blood viscosity and raises thromboembolic risk. The FDA's prescribing guidance for testosterone products includes erythrocytosis as a labeled risk requiring dose adjustment or discontinuation. Routine monitoring of CBC is standard of care.

Cardiovascular surveillance. The relationship between TRT and cardiovascular outcomes has been debated for over a decade. The TRAVERSE trial, published in the New England Journal of Medicine in 2023, found that testosterone therapy in middle-aged and older men with hypogonadism and elevated cardiovascular risk did not increase MACE (major adverse cardiovascular events) compared to placebo, offering some reassurance. However, the trial also found a higher incidence of atrial fibrillation and pulmonary embolism in the testosterone group, warranting continued vigilance.

Prostate health. Testosterone does not cause prostate cancer by current evidence, but it can stimulate growth of existing androgen-sensitive prostate tissue. PSA monitoring at baseline and at regular intervals is standard practice per Endocrine Society clinical guidelines.

Bone mineral density. This is frequently overlooked in public discussion of TRT but is clinically relevant. Hypogonadism is a significant driver of bone loss in men, and TRT has been shown to increase bone mineral density. Stopping therapy without confirmed HPG recovery may accelerate bone loss in older men already at osteoporosis risk.

The HGH Piece: What the Evidence Says

Stallone admitted past use of recombinant human growth hormone. The HealthRX Medical Team will not speculate on whether any HGH use continued beyond what he acknowledged. What is clinically useful here is context.

Exogenous HGH in non-deficient adults has a narrow and contested evidence base. Claimed benefits including muscle gain, fat loss, and recovery enhancement are partially supported by short-term pharmacological studies, but the long-term risk profile includes insulin resistance, edema, carpal tunnel syndrome, and, in high doses, potential promotion of IGF-1-mediated cell growth. The FDA has approved GH replacement only for documented adult growth hormone deficiency, not for body composition or anti-aging purposes in otherwise healthy adults.

Combining exogenous testosterone and HGH is, in pharmacological terms, synergistic for lean mass accrual, because GH and IGF-1 act on skeletal muscle through pathways that are complementary to androgen receptor signaling. This combination is widely discussed in bodybuilding literature and has been documented in case series, though formal randomized trial data in aging men is limited.

A Nuanced Takeaway for Men Watching This Story

Stallone's public profile has made him influential in the men's health space in a way that is genuinely worth examining carefully. Men in their 50s and 60s frequently cite his physique and his openness about hormone use when asking their own physicians about TRT. That is not inherently problematic; it has moved a legitimate medical conversation into mainstream discourse.

The clinical message the HealthRX Medical Team wants to pair with that cultural influence is this: long-term TRT is a serious, monitored medical intervention, not a permanent supplement. The decision to start, continue, or stop should be grounded in lab values, symptom assessment, and individualized risk profiling. The fact that a celebrity has used testosterone for decades and publicly reported benefit does not replace that framework. Stallone's story is a starting point for the conversation, not a clinical protocol.

Frequently asked questions

›
›
›
›
›
›

References

  • Bhasin S, et al. "Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2018. https://pubmed.ncbi.nlm.nih.gov/29562364/
  • Lincoff AM, et al. "Cardiovascular Safety of Testosterone-Replacement Therapy." N Engl J Med. 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2212948
  • Bhasin S, et al. "The Effects of Supraphysiologic Doses of Testosterone on Muscle Size and Strength in Normal Men." N Engl J Med. 2001. https://www.nejm.org/doi/full/10.1056/NEJMoa010085
  • Liu PY, et al. "Determinants of the Rate of Androgen-Induced Azoospermia in Normal Men." J Clin Endocrinol Metab. 2014. https://pubmed.ncbi.nlm.nih.gov/25100380/
  • Ramasamy R, et al. "Testosterone Recovery after Cessation of TRT in Older Men." Andrology. 2020. https://pubmed.ncbi.nlm.nih.gov/32150337/
  • Snyder PJ, et al. "Effect of Testosterone Treatment on Body Composition and Muscle Strength." N Engl J Med. 2016. https://pubmed.ncbi.nlm.nih.gov/26886521/
  • FDA Prescribing Information: AndroGel (testosterone gel). https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204073s000lbl.pdf
  • Rudman D, et al. "Effects of Human Growth Hormone in Men over 60 Years Old." N Engl J Med. 1990. https://pubmed.ncbi.nlm.nih.gov/10352397/
  • Endocrine Society Clinical Practice Guidelines: Testosterone Therapy in Men with Hypogonadism. https://www.endocrine.org/clinical-practice-guidelines/testosterone-therapy-in-men-with-hypogonadism